IONS resolved early, and it resolved cleanly. FDA approved TRYNGOLZA® for adults with severe hypertriglyceridemia as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis. That is better than a narrow triglyceride-only label. It moves IONS off the live board and into the win column.
ACHV and LNTH went the other direction. Both moved into the CMC-reset bucket. ACHV received the expected CRL for cytisinicline, tied to third-party manufacturing / inspection issues and incomplete final labeling. LNTH received a CRL for LNTH-2501 after a three-month manufacturing-related review extension.
That leaves the live stack tighter: ARQT / UNCY today, then VERA next week, followed by CELC, MNKD, OTLK, and VTRS into late July.
|
✓
|
IONS / TRYNGOLZA® — APPROVED · Jun 24
FDA approved TRYNGOLZA for adults with severe hypertriglyceridemia as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis. The important read is the label: this was not just triglyceride-lowering language.
|
|
!
|
ACHV / CYTISINICLINE — CRL · Jun 20 / Jun 22
FDA declined to approve cytisinicline for smoking cessation. This was expected after Achieve had already guided to a likely CRL tied to third-party manufacturing / inspection issues. The company continues to point to a Q4 2026 resubmission and potential H1 2027 approval window.
|
|
!
|
LNTH / LNTH-2501 — CRL · Jun 26
The clean diagnostic-imaging setup became another manufacturing reset. FDA declined to approve LNTH-2501 because of unresolved issues at a third-party manufacturing facility. The company said FDA did not identify concerns with the submitted data or the safety / efficacy of LNTH-2501.
|
|
+
|
ARQT / ZORYVE® — DECISION-DAY WATCH · Jun 29
ZORYVE cream 0.3% is now a same-day PDUFA watch for plaque psoriasis in children ages 2–5. This remains the cleaner label-expansion setup on the live board.
|
|
+
|
UNCY / OLC — DECISION-DAY WATCH · Jun 29
Unicycive is the more volatile same-day small-cap clock. OLC is a resubmitted NDA for hyperphosphatemia in CKD patients on dialysis, with the prior CRL tied to manufacturing deficiencies rather than stated clinical or safety concerns.
|
|
X
|
CORT / RELACORILANT — STILL EXCLUDED
The raw file still shows a July 11 relacorilant PDUFA, but that entry remains stale. FDA already approved relacorilant with nab-paclitaxel for the relevant platinum-resistant ovarian cancer indication.
|
| PDUFA | Window | Ticker | Event | PoA |
| Mon Jun 29 | Mon Jun 29 | ARQT | ZORYVE® cream / psoriasis, ages 2–5 | 99% |
| Mon Jun 29 | Mon Jun 29 | UNCY | OLC / CKD dialysis hyperphosphatemia | 72% |
| Tue Jul 7 | Tue Jul 7 | VERA | atacicept / IgA nephropathy | 78% |
| Fri Jul 17 | Fri Jul 17 | CELC | gedatolisib / HR+ HER2- PIK3CA WT BC | n/s |
| Sun Jul 26 | Fri 24 / Mon 27 | MNKD | FUROSCIX ReadyFlow Autoinjector | 73% |
| Wed Jul 29 | Wed Jul 29 | OTLK | LYTENAVA / wet AMD | 72% |
| Thu Jul 30 | Thu Jul 30 | VTRS | MR-100A-01 / low-dose-estrogen CHC weekly patch | 92.5% |
| ARQT $ARQT · ZORYVE® cream · psoriasis ages 2–5 | PDUFA: Mon Jun 29 PoA 99% |
This is the clean label-expansion event in the late-June board. ZORYVE cream is already approved and commercialized for plaque psoriasis in older patients. The current sNDA seeks to extend use down to children ages 2–5. The watch item is label detail: age, severity, use language, and how cleanly FDA lets Arcutis carry the pediatric expansion.
| UNCY $UNCY · OLC · CKD dialysis hyperphosphatemia | PDUFA: Mon Jun 29 PoA 72% |
This is the live small-cap volatility node. OLC is an oral phosphate binder designed to reduce pill burden in CKD patients on dialysis. The prior FDA issue was manufacturing-driven, not a stated clinical efficacy or safety rejection. That makes this a manufacturing remediation decision more than a clean drug-efficacy binary.
| VERA $VERA · atacicept · IgA nephropathy | PDUFA: Tue Jul 7 PoA 78% |
VERA becomes the next major regulatory sequence after ARQT / UNCY. The July 7 decision is the first step. The next step is the ORIGIN 3 eGFR confirmatory analysis expected in Q3 2026, followed by a potential Q4 2026 sBLA for full approval if the eGFR data are supportive.
| CELC $CELC · gedatolisib · HR+ HER2- PIK3CA WT BC | PDUFA: Fri Jul 17 n/s |
CELC stays inside the July board. FDA accepted the NDA and granted Priority Review for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer. Keep the filed indication separate from broader breast-cancer read-throughs or subgroup noise.
| MNKD $MNKD · FUROSCIX ReadyFlow Autoinjector | PDUFA: Sun Jul 26 PoA 73% |
MNKD is more device / delivery execution than new-drug efficacy. FUROSCIX is already an established furosemide product. ReadyFlow is an autoinjector / delivery-format sNDA, with a weekend action date that may resolve Friday July 24 or Monday July 27.
| OTLK $OTLK · LYTENAVA / ONS-5010 · wet AMD | PDUFA: Wed Jul 29 PoA 72% |
OTLK remains the scarred July resubmission. The upside case is FDA accepting the latest package and clearing an on-label ophthalmic bevacizumab product. The risk case is prior FDA rejection history and the burden around regulatory completeness.
| VTRS $VTRS · MR-100A-01 · low-dose-estrogen CHC weekly patch | PDUFA: Thu Jul 30 PoA 92.5% |
VTRS remains the lower-volatility late-July item. This is a 505(b)(2) combined hormonal contraceptive patch application, not a high-drama novel-mechanism biotech binary. The watch item is label language around BMI, adhesion, estrogen exposure, and use population.
The board just changed shape.
IONS moved into the win column early, and the label was strong: triglyceride reduction plus acute pancreatitis-risk reduction for adults with severe hypertriglyceridemia.
ACHV and LNTH moved into the CMC-reset bucket. That makes today’s live queue smaller and more concentrated.
| ARQT | / | UNCY | → | VERA | ||
| CELC | → | MNKD | / | OTLK | / | VTRS |
The cleanest live setup is ARQT. The main small-cap volatility node is UNCY. The biggest de-risked win is IONS. The biggest negative update is LNTH moving from high-confidence diagnostic approval watch to manufacturing-reset story.
That is the queue.
Informational only · Not investment advice · Biotech carries risk of total loss